New Pancreatic Cancer Trial Launches
A new Phase 3 study is testing a novel drug combination to see if it can improve outcomes for patients with metastatic pancreatic cancer.
Updated on Oct. 26, 2026 in Cancer
Immuneering Corporation has launched the Phase 3 MAPKeeper 301 clinical trial, investigating a new combination therapy for patients with metastatic pancreatic ductal adenocarcinoma. The study evaluates whether adding the drug atebimetinib to standard chemotherapy can improve survival outcomes.
Why it matters
Pancreatic cancer remains a difficult disease to treat, and this global study aims to determine if a novel targeted approach can outperform current standard-of-care chemotherapy. Researchers are testing this combination to see if it extends life for patients diagnosed with the metastatic form of the disease.
A Phase 2a study of 55 patients reported an objective response rate of 36% and a disease control rate of 82%. These preliminary findings from the early-stage study now serve as the basis for the ongoing Phase 3 trial.
The players
Immuneering Corporation
A biotechnology company focused on the development of medicines for patients with cancer and other serious diseases.
The details
The trial utilizes a 1:1 randomization model to compare the standard-of-care chemotherapy regimen with an experimental arm containing 320 mg of the drug atebimetinib. Atebimetinib is designed to be taken once daily alongside modified gemcitabine and nab-paclitaxel. Investigators are stratifying participants by geographical region, presence of liver metastases, and performance status to ensure a balanced comparison.
Timeline
Dosing for the MAPKeeper 301 study began in June 2026.
The ESMO Congress 2026 was held in Madrid from October 23-27, 2026.
The trial-in-progress poster was formally presented on October 25, 2026.
Health Landscape
The MAPKeeper 301 trial design was unveiled at the ESMO Congress 2026, marking a new step in pancreatic cancer research. This study reflects the broader trend of testing targeted inhibitors alongside traditional cytotoxic chemotherapy regimens to address poor outcomes in advanced solid tumors.
This study is in its early stages, and results are not yet available to guide clinical treatment decisions. Patients interested in learning about eligibility for this or other clinical trials should discuss these options with their oncologist.
The takeaway
Clinical trials are essential to identifying new treatment strategies for complex conditions like metastatic pancreatic cancer. Discuss the feasibility and availability of participation in active oncology studies with your physician if you are currently managing a diagnosis.
Further reading
For more information on the current landscape of oncology research and treatment, visit our Cancer section.
More information
View the formal trial methodology and project updates via Immuneering publications and poster documents.
